PURPOSE: To evaluate refractive status among the babies treated with either laser photocoagulation or received intravitreal ranibizumab injection for the treatment of ROP. METHODS: This is an institution based retrospective cohort study, in a tertiary eye care centre of Kolkata. Total of 90 preterm infants with ROP were classified into three groups A, B and C respectively. In each group, there were 30 babies. All babies of group A, were termed delivered with more than 2.5 kg weight. In group B, all babies underwent laser photocoagulation therapy for type1 ROP. In Group C, all babies received intravitreal ranibizumab injection for type 1 ROP. All babies were followed up at 1st, 3rd, and 6th months of their respective age. In each visit, Indirect Ophthalmoscopy and cycloplegic refraction were performed. RESULTS: The final refractive error (mean spherical equivalent) after 6 months in three groups were +0.77, –1.83 and –0 .525 respectively. CONCLUSION: A significant refractive error (myopia) developed in two groups B and C. Myopic changes was more with laser photocoagulation group infants at 6 months as compared to intravitreal Ranibizumab treated group. Our study revealed that myopia was influenced by laser photocoagulation than intravitreal Ranibizumab. This myopic change begins before the age of 6 months age.